Psychiatric Digital Biomarkers Market By Component (Hardware, Software, Services), By Biomarker Type (Behavioral Biomarkers, Physiological Biomarkers, Cognitive Biomarkers, Social Interaction Biomarkers), By Psychiatric Disorder (Depression and Major Depressive Disorder (MDD), Schizophrenia, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Disorder (OCD), Others), By Technology (Smartphone-based Tracking, Wearable Biosensors, Voice and Speech Analytics, EEG Monitoring, Artificial Intelligence and Machine Learning, Cloud-based Platforms, Others), By Application (Remote Monitoring, Treatment Personalization, Digital Therapeutics, Post-discharge Monitoring, Suicidal Ideation Detection, Others), By End-user (Hospitals and Mental Health Clinics, Research Institutes, Pharmaceutical and Biotech Companies, Digital Therapeutics Companies, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035.

---

What trends will shape the Psychiatric Digital Biomarkers Market in the coming years?

The Psychiatric Digital Biomarkers Market accounted for USD 635.03 Million in 2024 and USD 794.11 Million in 2025 is expected to reach USD 7425.32 Million by 2035, growing at a CAGR of around 25.05% between 2025 and 2035. It is expected that the psychiatric digital biomarkers market will develop fast due to the growing desire to keep remote control of people with mental issues and innovations in the usage of AI and machine learning in predictive analysis. Real-time data collection in the tracking of early diagnosis and personalized treatment is being made possible due to advances in wearable technology and smartphone-based tracking.

The use of digital phenotyping is on the rise as a tool for attracting non-invasive concepts of behavioral pattern knowledge. Telepsychiatry and digital therapeutics are increasing the scope of the market due to evolving acceptance. Regulatory bodies are slowly coming to terms with accommodating digital mental health developments. Innovation is driven by the growth in mental health awareness and investments in digital health startups. Collectively, these trends are transforming how psychiatric care is delivered into one that is more data-driven, accessible, and preventive.

What do industry experts say about the Psychiatric Digital Biomarkers Market trends?

“The future of psychiatric care lies in continuous, real-world monitoring enabled by digital biomarkers. These tools will not only revolutionize diagnosis but also empower patients and clinicians with data-driven insights.”

• Dr. Arshya Vahabzadeh, Chief Medical Officer, Brain Power.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Psychiatric Digital Biomarkers Market?

How is rising mental health disorder prevalence driving demand for digital psychiatric solutions?

The Psychiatric Digital Biomarkers Market is currently advancing at a high rate as the level of mental health problems is increasing on a global scale. In 2022, it is estimated that up to 23.1% of American adults had some type of mental illness, and these data indicate the necessity of supplementary monitoring mechanisms to be scalable and efficient. The growing pressure is fueling the demand for digital in the psychiatric sector that can provide real-time, objective insights into patient behavior and emotions.

Conventional in-person treatment of psychiatric problems can be patchy and sporadic, and digital biomarkers deliver real-time data using smartphones, wearables, and AI platforms. These resources make it possible to detect mood disorders already in the early stages and promptly take action against them, anxiety, and cognitive decline. Due to the increased need for patients to receive accessible mental healthcare, digital tools provide opportunities to scale their access, particularly in underserved communities. These tools are also beneficial to clinicians since they provide insight based on data to individualize the treatment therapy. Monitoring in between visits is enhanced by the integration of the digital biomarkers and a lower probability of relapse. As the number of mental cases has been on the increase among people of all ages, psychiatric digital technologies are rapidly finding their way into contemporary mental health care provision.

Why does AI integration enhance diagnosis accuracy and accelerate market adoption across care settings?

A flood of artificial intelligence adoption in the Psychiatric Digital Biomarkers Market is being observed due to the significant contribution of artificial intelligence in making the overall diagnosis accurate and speeding up the adoption process in a care setting. A PubMed meta-analysis has shown that machine learning models employing AI demonstrated a pooled diagnostic accuracy of 85% in psychiatric settings as compared to conventional methods. The precision means that clinicians can make more confident distinctions between more nuanced conditions, e.g., between bipolar disorder and unipolar depression. AI is strong and has a bigger capacity to process substantial quantities of inconsistent information, such as speech, sleep, cardiac rate, and behavioral patterns, and find minor hints unnoticeable during medical observation.

The process includes incorporating the systems into care pathways in order to sustain objective, homogeneous, and scalable decisions. Consequently, hospitals, clinics, and telepsychiatry platforms are getting more interested in implementing AI tools in order to increase confidence levels in the diagnosis and improve clinical effectiveness. In addition, AI helps tailor treatment since it can predict the interventions that could be most effective in the case of individual patients. This facilitates greater approval among health practitioners and healthcare companies. Finally, the use of AI is transforming psychiatric diagnostics and is making mental health care more accurate, sensitive, and accessible.

How do data privacy concerns hinder the widespread adoption of digital psychiatric biomarker tools?

The privacy of data is a major factor that threatens the forthcoming occurrence of digital psychiatric biomarker measures since it poses ethical, legal, and confidentiality issues. Because such tools gather very sensitive behavioral, cognitive, and physiological data, which is frequently passively monitored on smartphones or wearables, end-users fear how their mental health data will be stored, shared, and utilized. The concern about being stigmatized, discriminated against, or having their personal psychiatric information used appropriately puts people off from using these technologies to the full extent.

Digital health platforms have few data governance policies, which leads to even more doubts. Also, there is an uneven approach to the definition of laws pertaining to privacy in different jurisdictions, which makes it hard to regionalize solutions at the level of companies. The care providers are also reluctant to use tools that can put them under legal liability or mistrust the patient. Lack of adequate controls on the use of third-party data, such as insurers or other technology companies, intensifies such impediments. Anonymization, cybersecurity, and consent frameworks are weak without it, which is why adoption is low. Precisely, these issues of privacy must be resolved in the process of attracting confidence from the populace and are also related to the ethical implementation of digital psychiatric biomarkers.

How can underserved regions benefit from scalable, remote psychiatric biomarker-based healthcare models?

The Psychiatric Digital Biomarkers Market has an opportunity to revolutionize mental care in underserved states, where the gaps in treatment are disturbingly large. WHO estimates that 85-76% of individuals in low- and middle-income nations with mental diseases lack any form of treatment, stressing the necessity of scalable digital interventions. Offering access to continuous mental health monitoring, communities without specialists acquire the possibility of conducting remote assessments using biomarkers through smartphones and wearables that will help them understand whether changes in their condition are caused by some medical conditions or realities. The tools facilitate the task-shifting practice, allowing non-specialist workers to provide screening and manage progress.

The remote models have caused mental health services to reach children, adolescents, and rural residents due to the minimal infrastructure that serves as a geographic and cost obstacle to receiving mental health services. Information in digital platforms is also objective, like effects in sleep and speech changes that can improve early detection and minimize physical disorders. This technology can bring culturally sensitive care in places where there is stigma and a lack of workforce. Moreover, centralized data collection can be used to inform the public health approach and resource allocation. The bottom line is that available, remote models of psychiatric biomarkers provide hope to millions of people who, at present, do not have mental health care.

What new prospects exist for pharma firms using biomarkers in psychiatric clinical trial optimization?

The Psychiatric Digital Biomarkers Market provides emerging businesses to pharmaceutical companies to streamline psychiatric clinical trials since the biomarkers allow objective and quantitative analysis of patients to streamline clinical trial design and participant selection. The FDA found that the application of genomic biomarkers in neuropsychiatry clinical trials can enhance the success rates of drug development, especially target engagement and stratification of patients. Using digital biomarkers that include voice patterns, sleep-recorded metrics, and EEG signatures administered by pharma companies, responders can be distinguished earlier on, and the heterogeneity of a trial can be minimized.

This allows selection of trial cohorts with the participants it is most likely to help, thus raising statistical power and lowering the sample size to be used. Also, constant screening of actual in-real-world digital signals enhances surveillance of safety and adherence to treatments. The biomarkers can also facilitate adaptive trial designs in which dose or treatment arms may be altered following an interim digital readout. The end-point approval and acceptance of regulations are sped up by feeding the AI-based analytics. Today, pacts between pharma and digital health vendors or the government consortia are promoting uniform biomarker lines. On the whole, digital biomarkers provide significant solutions to increase the effectiveness, accuracy, and patient-oriented nature of psychiatric drug trials.

What are the key market segments in the Psychiatric Digital Biomarkers industry?

Based on the biomarker type, the Psychiatric Digital Biomarkers Market is classified into behavioral biomarkers, physiological biomarkers, cognitive biomarkers, and social interaction biomarkers. The type of biomarkers indicates that behavioral biomarkers are the current leading segment, poised at such predominance because they are gathered easily through smartphones and wearables. These involve the speech patterns, facial expressions, and smartphone use, and can provide real-time feedback of the behavior.

Sleep patterns and heart rate variability become prominent physiological biomarkers that emerge with the current usage of biosensors and wearables.

Biomarkers (i.e., cognition markers) are taking shape, notably in conditions such as ADHD and schizophrenia, whereby attention, memory, and decision-making areas are being set up and analyzed. Although biomarkers of social interaction are in their infancy, they have the potential to identify mood change (or isolation) based on digital communication patterns. There is a rising need for multi-modal biomarkers uniting various deployments into one to provide a comprehensive picture of the patient. Such a division into biomarkers is critical in facilitating early diagnosis and individualization of treatment, and prevention of relapses in mental health management.

Based on the psychiatric disorder, the Psychiatric Digital Biomarkers Market is classified into Depression and Major Depressive Disorder (MDD), Schizophrenia, Post-Traumatic Stress Disorder (PTSD), Attention Deficit Hyperactivity Disorder (ADHD), Obsessive-Compulsive Disorder (OCD), and Others. Major depressive disorder (MDD) is the most popular class in the Psychiatric Digital Biomarkers Market since they have a high global prevalence, and the necessity of continuous real-time monitoring is high as well. Close behind are the anxiety disorders, where smartphone-based tracking and voice analytics are increasingly offered to detect manifestations early in the process. The area of schizophrenia and bipolar disorder is already growing because digital tools provide the opportunity to maintain more control over cognitive and behavioral changes.

PTSD is becoming increasingly common, particularly in those exposed to trauma or people in the military, where digital phenotyping will help monitor symptoms. There is a growing interest in ADHD and OCD segments, especially in the use of digital cognitive assessment in the pediatric and young adult populations. Substance use disorders may become an additional field in which passive data and behavior could help prevent relapses. On the whole, the market is moving away from the multi-disorder support platforms, which allow greater psychiatric use.

Which regions are leading the Psychiatric Digital Biomarkers Market, and why?

The North America Psychiatric Digital Biomarkers Market is leading due to the it has superior digital health infrastructure, a good level of mental health awareness rate, and immense acceptance of wearable and mobile devices. The United States, especially due to the high investments in digital therapeutics, friendly reimbursement models, and the use of AI in the field of psychiatry treatment.

The area is also disadvantaged by the high rate of mental health disorders, which calls for monitoring and personalized support in real time. Another factor that is promoting rapid innovation is the development of digital biomarker solutions by many startups and tech giants. Clinical validation and commercialization are being enhanced by favorable regulatory approval from regulatory authorities such as the FDA. Overall, North America is a leader in terms of digital transformation in terms of psychiatric care.

The Asia Pacific Psychiatric Digital Biomarkers Market is growing due to the growing awareness of mental health, smartphone penetration and wearable penetration, and rising digital health initiatives. Nations such as China, India, the US, Japan, and South Korea are also experiencing unprecedented cases of mental conditions, hence the necessity of conveniently priced and efficient diagnostic products. Telehealth platforms and AI-based mental health solutions provided by the governments and the private sectors are investing in them to resolve the gap in psychiatric care.

The rising population and the expanding tech-savvy middle class in the region are enhancing the development of mobile mental health applications and digital biomarkers. In addition, the insufficient number of qualified specialists in the field of mental health topics is stimulating healthcare systems to resort to digital options in the segment of screening and monitoring. Due to constant advancement in technology and government support, the same in Asia-Pacific will experience a multi-fold increase in the next ten years.

What does the competitive landscape of the Psychiatric Digital Biomarkers Market look like?

The Psychiatric Digital Biomarkers Market competitive environment is quickly changing as the leading players devote attention to innovation, integration of AI, and clinical appraisal. The most promising companies, like Koneksa Health, Empatica, Sonde Health, Biogen, VivoSense, IXICO, and Clario, have platforms that are focused on relying on the information about behavior, physiology, and cognition to supplement psychiatric care. To increase the scope of digital biomarkers, these companies are entering strategic combinations with medical services, educational establishments, and drug organizations. Machine learning and real-world data are gaining a lot of prominence to enhance predictive accuracy and create customized treatment plans.

New investors are also joining the field, with startups able to offer flexibility and innovative solutions to underrepresented populations in the psychiatry sector. Mindstrong Health released in February 2025 an AI-based pilot study that exploited smartphone typing and scrolling behaviors as signatures of the depressive episode in U.S. veterans, the first major milestone towards scalable mental health surveillance. Market players are also putting in regulatory acceptance and repayment methods to guarantee business success. The competitive situation is also supplemented by increasing consumer needs in terms of remote psychiatric services and data-based diagnostics. In general, the landscape is innovative and strategic in its collaboration and has created an urgent drive toward addressing the unmet mental health care need.

Psychiatric Digital Biomarkers Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Psychiatric Digital Biomarkers industry?

• In July 2025, Nordic Capital acquired healthcare analytics firm Arcadia Solutions, aiming to enhance AI-powered data platforms; while Arcadia isn’t exclusive to psychiatry, this signals growing investment into AI-driven health analytics that can be leveraged for digital mental health
• In February 2025, Mindstrong Health launched an AI-driven pilot study using smartphone typing and scrolling patterns to detect depressive episodes among U.S. veterans, marking a significant step toward scalable, real-time mental health monitoring.

Report Coverage:

By Component

• Hardware
• Software
• Services

By Biomarker Type

• Behavioral Biomarkers
• Physiological Biomarkers
• Cognitive Biomarkers
• Social Interaction Biomarkers

By Psychiatric Disorder

• Depression and Major Depressive Disorder (MDD)
• Schizophrenia
• Post-Traumatic Stress Disorder (PTSD)
• Attention Deficit Hyperactivity Disorder (ADHD)
• Obsessive-Compulsive Disorder (OCD)
• Others

By Technology

• Smartphone-based Tracking
• Wearable Biosensors
• Voice and Speech Analytics
• EEG Monitoring
• Artificial Intelligence and Machine Learning
• Cloud-based Platforms
• Others

By Application

• Remote Monitoring
• Treatment Personalization
• Digital Therapeutics
• Post-discharge Monitoring
• Suicidal Ideation Detection
• Others

By End-user

• Hospitals and Mental Health Clinics
• Research Institutes
• Pharmaceutical and Biotech Companies
• Digital Therapeutics Companies
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Mindstrong Health Inc.
• Sonde Health Inc.
• Koneksa Health Inc.
• Empatica Inc.
• Biogen Inc.
• IXICO plc
• VivoSense Inc.
• Clario Inc.
• Happify Health
• Woebot Health Inc.
• Neurotrack Technologies Inc.
• Quartet Health Inc.
• Big Health Ltd.
• Behavioral Signals Technologies Inc.
• Ginger.io Inc.

Frequently Asked Questions (FAQs)